ZOM
Zomedica Corp.
Set alert
52-week range unavailable
- YTD
- -18.92%
- 1 year
- -30.00%
- Open
- 0.092
- Prev close
- 0.0973
- Mkt cap
- 117.59M
- Vol
- 790.94K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.092
- High
- 0.0973
- Forward P/E
- 0.00
- Beta
- 1.06
- Short ratio
- 17.24
- Inst. own
- 8.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.12568
- 200-d avg
- 0.139015
- 1y target
- 0.25
Key statistics
- Market cap
- 117.59M
- Enterprise value
- 42.04M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 4.51
- Price / book
- 0.49
- EPS (TTM)
- -0.07
- Beta
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -214.69%
- Revenue (TTM)
- 26.08M
- Revenue growth
- 1.80%
- Free cash flow
- -23.17M
- Total cash
- 79.51M
- Total debt
- 2.29M
- Return on equity
- -23.92%
- Shares outstanding
- 979.95M
- Short % of float
- 5.21%
- 50-day average
- 0.12568
- 200-day average
- 0.139015
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.007.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- zomedica.com
News
- Zomedica Corp. (ZOMDF) Discusses Clinical Program and Evidence-Driven Adoption in Veterinary Products Transcript
- Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption
- Zomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios Transcript
- Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices
- Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica's Marketing Engine: How Demand Becomes Revenue
- Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call Transcript
- Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation
- Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
- Zomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine Transcript
- Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic
Your note
Sign in to keep a note on ZOM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLAIR ANTHONY K | Chief Operating Officer | Purchase | Nov 7, 2024 | 400,000 |
| DONATO PETER L | Chief Financial Officer | Purchase | Jun 9, 2024 | 25,000 |
| HEATON LARRY C II | Chief Executive Officer | Purchase | Nov 10, 2024 | 500,000 |
| KLASS RUSSELL KEVIN | Officer | Purchase | Nov 10, 2024 | 1,500,050 |
| POWERS JOHNNY D | Director | Purchase | Nov 10, 2024 | 2,425,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.93% | 48,326,991 | 5.80M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.01% | 9,929,716 | 1.19M | Sep 29, 2024 |
| Blackrock Inc. | 1.00% | 9,821,071 | 1.18M | Sep 29, 2024 |
| State Street Corporation | 0.36% | 3,509,881 | 421.19K | Sep 29, 2024 |
| Brown Brothers Harriman & Co | 0.25% | 2,466,532 | 295.98K | Sep 29, 2024 |
| Northern Trust Corporation | 0.18% | 1,797,902 | 215.75K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.38% | 33,158,730 | 3.98M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 13,413,683 | 1.61M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.57% | 5,583,069 | 669.97K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 1,652,964 | 198.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 1,320,271 | 158.43K | Oct 30, 2024 |
| Vanguard Balanced Index Fund | 0.08% | 759,400 | 91.13K | Sep 29, 2024 |